Captopril
Drug Category | Drug | IHD Dosing | Administration Timing Around HD Session |
---|---|---|---|
ACE Inhibitors | Captopril | 12.5-50mg PO Q24H | Administer Post HD |
Molecular Weight (Da) | Excreted Unchanged (%) | Normal Half-Life (Hours) | ESRD Half-Life (Hours) | Plasma Protein Binding (%) | Volume of Distribution (L/kg) | Dialytic Plasma Clearance (ml/min) | % Dialyzed |
---|---|---|---|---|---|---|---|
217 | 40-50 | 2-3 | 21-32 | 25-30 | 0.7-3 | N/A | 40 (high flux) |
References:
- Aronoff GR, Bennett WM, Berns JS, Brier ME, Kasbekar N, Mueller BA, et al. Drug Prescribing in Renal Failure. Philadelphia: American College of Physicians;2007.
- DrugBank [Online]. 2012 Apr 12 [cited 2012 May 6]; Available from: URL: http://www.drugbank.ca/drugs/DB01197
- Inrig J. Antihypertensive agents in hemodialysis patients: a current perspective. Seminars in dialysis. 2010; 23(3):290-7.
- Nonoguchi H, Kiyama S, Kitamura K, et al. Long-term plasma levels and dose modulation of alacepril in patients with chronic renal failure. Hypertension research : official journal of the Japanese Society of Hypertension. 2008;31(1):29-36. Available at: http://www.ncbi.nlm.nih.gov/pubmed/18360015.
- Zheng S, Nath V, Coyne D. ACE inhibitor-based, directly observed therapy for hypertension in hemodialysis patients. American journal of nephrology. 2007;27(5):522-9.